Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting the gut microbiome to treat the osteoarthritis of obesity
Eric M. Schott, Christopher W. Farnsworth, Alex Grier, Jacquelyn A. Lillis, Sarah Soniwala, Gregory H. Dadourian, Richard D. Bell, Madison L. Doolittle, David A. Villani, Hani Awad, John P. Ketz, Fadia Kamal, Cheryl Ackert-Bicknell, John M. Ashton, Steven R. Gill, Robert A. Mooney, Michael J. Zuscik
Eric M. Schott, Christopher W. Farnsworth, Alex Grier, Jacquelyn A. Lillis, Sarah Soniwala, Gregory H. Dadourian, Richard D. Bell, Madison L. Doolittle, David A. Villani, Hani Awad, John P. Ketz, Fadia Kamal, Cheryl Ackert-Bicknell, John M. Ashton, Steven R. Gill, Robert A. Mooney, Michael J. Zuscik
View: Text | PDF
Research Article Inflammation Microbiology

Targeting the gut microbiome to treat the osteoarthritis of obesity

  • Text
  • PDF
Abstract

Obesity is a risk factor for osteoarthritis (OA), the greatest cause of disability in the US. The impact of obesity on OA is driven by systemic inflammation, and increased systemic inflammation is now understood to be caused by gut microbiome dysbiosis. Oligofructose, a nondigestible prebiotic fiber, can restore a lean gut microbial community profile in the context of obesity, suggesting a potentially novel approach to treat the OA of obesity. Here, we report that — compared with the lean murine gut — obesity is associated with loss of beneficial Bifidobacteria, while key proinflammatory species gain in abundance. A downstream systemic inflammatory signature culminates with macrophage migration to the synovium and accelerated knee OA. Oligofructose supplementation restores the lean gut microbiome in obese mice, in part, by supporting key commensal microflora, particularly Bifidobacterium pseudolongum. This is associated with reduced inflammation in the colon, circulation, and knee and protection from OA. This observation of a gut microbiome–OA connection sets the stage for discovery of potentially new OA therapeutics involving strategic manipulation of specific microbial species inhabiting the intestinal space.

Authors

Eric M. Schott, Christopher W. Farnsworth, Alex Grier, Jacquelyn A. Lillis, Sarah Soniwala, Gregory H. Dadourian, Richard D. Bell, Madison L. Doolittle, David A. Villani, Hani Awad, John P. Ketz, Fadia Kamal, Cheryl Ackert-Bicknell, John M. Ashton, Steven R. Gill, Robert A. Mooney, Michael J. Zuscik

×

Figure 6

Oligofructose mitigates obesity-induced synovial inflammation, chondrocyte hypertrophy, and meniscal mineralization.

Options: View larger image (or click on image) Download as PowerPoint
Oligofructose mitigates obesity-induced synovial inflammation, chondrocy...
(A) To assess the inflammatory signature of joints of obese mice supplemented with oligofructose or cellulose, MCP-1 and Tnf expression was examined. MCP-1 was detected via immunofluorescence, with DAPI counterstaining of nuclei. The blue dotted lines outline articular cartilage on the femoral condyle (F, femur), the yellow dotted lines demarcate the margins of the synovial membrane, and the white scale bar represents 50 µm. Tnf expression was assessed via IHC, with synovial staining identified with red arrows and black scale bars representing 200 µm (M, meniscus; T, tibia). (B) To evaluate articular chondrocyte hypertrophic differentiation and cartilage matrix changes, Runx2, Mmp13, and Col10 expression was examined via IHC, with yellow dotted lines demarcating the tidemarks, red arrows pointing to chondrocytes or areas with positive staining, and black scale bars representing 50 µm (M, meniscus; T, tibia; F, femur). (C) Representative Safranin O/Fast Green–stained sections depict posterior medial joint margins with an osteophyte identified by a yellow asterisk in the obese-DMM-cellulose group and the black scale bar representing 200 µm (M, meniscus; T, tibia). (D) MicroCT imaging reveals mineralized structures in experimental joints, with mineralized menisci identified with white arrows and the white scale bar representing 1 mm. (E) Amira-based reconstruction of the raw dicoms from the microCT imaging was performed to enable quantitative segmentation of calcified menisci colored white with the white scale bar representing 1 mm. (F) Histology sections similar to those shown in C were used to quantify the number of osteophytes per histologic section in each experimental group. Data represent the group mean (± SEM), each symbol represents the average number of osteophytes per section from 3 levels within a joint (n = 5–7 joints), and the black dotted line represents the average in the lean-sham-cellulose negative control group. (G) Amira reconstructions similar to those depicted in E were used to quantify the volume of calcified meniscus in various experimental groups. Data represent the group mean (± SEM), each symbol represents the average calcified meniscus volume from each joint (n = 4 joints), and the black dotted line represents the average in the lean-sham-cellulose negative control group. Significant differences between groups in F and G were identified via 2-way ANOVA with a Tukey multiple comparison post-test (P values for the obesity effect are reported).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts